Physician profile
Jonathan Taffe
NPI 1912969163
$5,262.95
in general payments reported to CMS, 2019-2025
16 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $603 · 2021: $1,231 · 2022: $513 · 2023: $431 · 2024: $576 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.42 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,647.26 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $826.55 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $616.06 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $335.48 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.65 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $318.83 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $294.57 | 2019-2020 | |
| Abbvie INC. | $173.79 | 2023-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $124.17 | 2021 | |
| Daiichi Sankyo INC. | $116.44 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.77 | 2024 | Caplyta |
| Axsome Therapeutics, INC. | $110.46 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $88.33 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $82.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $68.60 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16.73 | 2024 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Taffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.